Substance / Medication

Carteolol

Overview

Active Ingredient
carteolol
RxNorm CUI
2116

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Research Evidence

Published studies and systematic reviews

Sort:
A prospective study of topical carteolol therapy in Chinese infants with superficial infantile hemangioma.
Gan Li-Qiang, Wang Hua, Ni Si-Li et al. · Pediatr Dermatol · 2018
PMID: 29243341RCT
Randomized, Controlled, Phase 3 Trials of Carteolol/Latanoprost Fixed Combination in Primary Open-Angle Glaucoma or Ocular Hypertension.
Yamamoto Tetsuya, Ikegami Toru, Ishikawa Yuji et al. · Am J Ophthalmol · 2016
PMID: 27565224Trial
[Long-acting carteolol hydrochloride 2% ophthalmic solution phase IV study--investigation of the effectiveness, safety and plasma concentration].
Kawase Kazuhide, Yamamoto Tetsuya, Muramatsu Tomoyuki et al. · Nippon Ganka Gakkai Zasshi · 2010
PMID: 21141077Trial
Beta 2-adrenoceptor-mediated intrinsic sympathomimetic activity of carteolol: an in vivo study.
Bruck Heike, Poller Ulrike, Lüssenhop Hendrik et al. · Naunyn Schmiedebergs Arch Pharmacol · 2004
PMID: 15526107Trial
[Efficacy and safety of long-acting carteolol 1% once daily. A double-masked, randomized study].
Trinquand C, Romanet J-P, Nordmann J-P et al. · J Fr Ophtalmol · 2003
PMID: 12660585Trial

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Carteolol (substance)
SNOMED CT
386866004
UMLS CUI
C0007299
RxNorm CUI
2116

Clinical Data

This intervention maps to 3 entities in the Ltrl knowledge graph.

3
Conditions
0
Biomarkers
0
Specialists
0
Symptoms

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.